Navigating the procurement of synthetic peptides for academic or private laboratory investigation requires strict adherence to quality, analytical transparency, and purity standards. When researchers seek to buy AOD 9604 peptide online, verifying HPLC purity profiles, mass spectrometry verification, and domestic manufacturing compliance is paramount. PX1 Research supplies reference-grade AOD 9604 manufactured in USA-based, GMP-compliant facilities exclusively for in vitro and preclinical research applications.
Navigating the procurement of synthetic peptides for academic or private laboratory investigation requires strict adherence to quality, analytical transparency, and purity standards. When researchers seek to buy AOD 9604 peptide online, verifying HPLC purity profiles, mass spectrometry verification, and domestic manufacturing compliance is paramount. PX1 Research supplies reference-grade AOD 9604 manufactured in USA-based, GMP-compliant facilities exclusively for in vitro and preclinical research applications.
To buy AOD 9604 peptide online for laboratory research, principal investigators and laboratory managers must source directly from verified domestic vendors that provide lot-specific certificates of analysis (COA). High-purity AOD 9604 should feature greater than 98% purity confirmed by high-performance liquid chromatography (HPLC) and electrospray ionization mass spectrometry (ESI-MS), accompanied by strict bacterial endotoxin screening.
Acquiring high-purity peptides for controlled laboratory environments demands thorough supplier evaluation. Researchers evaluating vendors for the purchase of AOD 9604 must look beyond simple market availability and focus on verifiable chemical integrity. Substandard reagents introduce unquantifiable variables into cellular assays and animal models, compromising experimental reproducibility and baseline data.
PX1 Research simplifies the procurement process for institutional and independent laboratories by maintaining an inventory of USA-manufactured reagents available via our catalog of research peptides. Every production batch undergoes rigorous testing by independent ISO 17025-accredited laboratories to confirm sequence identity, peptide content, and freedom from residual trifluoroacetic acid (TFA) salts or microbial contaminants. Orders dispatched from our dual fulfillment centers in California and Arizona ship same-day (Monday through Friday), ensuring rapid transit and cold-chain integrity for temperature-sensitive compounds.
AOD 9604 (Advanced Obesity Drug 9604) is a synthetic hexadecapeptide derived from the C-terminal region of human growth hormone (hGH), specifically encompassing amino acids 177 to 191, with an added tyrosine residue at the N-terminus to stabilize the peptide chain. Its systematic chemical structure is represented as Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe, containing an essential internal disulfide bridge between the cysteine residues at positions 7 and 14.
This conformational constraint created by the intramolecular disulfide bond is critical for the biological stability and receptor-binding characteristics of the molecule. Unlike parent hGH (191 amino acids), AOD 9604 isolates the lipolytic domain of the growth hormone molecule while omitting the N-terminal functional domains associated with insulin-like growth factor 1 (IGF-1) induction and systemic mitogenic signaling.
In physical form, high-purity AOD 9604 presents as a sterile, lyophilized white powder with a molecular weight of approximately 1815.1 Da. To preserve the structural integrity of the disulfide bridge and prevent oxidative degradation, synthesized batches must be stored under desiccated, sub-zero conditions prior to laboratory reconstitution. Detailed specifications and structural data can be examined in the PX1 Research reference library.
Preclinical investigations demonstrate that AOD 9604 interacts primarily with adipose tissue metabolic pathways through mechanisms independent of the classical growth hormone receptor (GHR) signaling cascade that drives hepatic IGF-1 release. In vitro assays using isolated adipocyte cultures show that the peptide stimulates lipolysis—the enzymatic breakdown of stored triacylglycerols into free fatty acids and glycerol—while simultaneously inhibiting lipogenesis, the process of de novo lipid synthesis.
Mechanistically, research suggests that AOD 9604 upregulated beta-3 adrenergic receptor expression in specific fat depots in animal models. By activating beta-adrenergic signaling pathways, the peptide stimulates intracellular cyclic adenosine monophosphate (cAMP) accumulation. Elevated cAMP activates protein kinase A (PKA), which subsequently phosphorylates hormone-sensitive lipase (HSL) and perilipin, facilitating the migration of lipolytic enzymes to lipid droplet surfaces.
Crucially, cellular models indicate that AOD 9604 operates without triggering signal transducer and activator of transcription 5 (STAT5) activation, which is the primary driver of systemic hGH-mediated cell proliferation and hyperinsulinemia. Consequently, preclinical literature frequently highlights AOD 9604 as a valuable model compound for dissecting isolated lipolytic pathways without introducing confounding systemic metabolic shifts associated with full-length GH or traditional growth hormone secretagogues.
In vitro and animal model studies over the past two decades have documented the metabolic and structural effects of AOD 9604 across diverse experimental paradigms. Initial preclinical rodent studies evaluating genetically obese (ob/ob) and diet-induced obese mice demonstrated significant reductions in body fat mass following chronic administration of the hexadecapeptide fragment, without observed alterations in lean muscle mass or daily feed consumption.
Beyond metabolic investigation, recent preclinical research has explored the regenerative potential of AOD 9604 in musculoskeletal and chondrocyte models. In vitro studies involving isolated articular chondrocytes suggest that AOD 9604 may enhance extracellular matrix synthesis by promoting hyaluronan production and upregulating collagen type II transcription. When combined with exogenous hyaluronic acid in lapine (rabbit) models of osteoarthritis, joint histology revealed improved cartilage structural preservation compared to controls.
Researchers investigating tissue remodeling and extracellular matrix dynamics frequently evaluate AOD 9604 alongside other repair-focused compounds, such as BPC-157 research peptide, to assess potential synergistic signaling pathways in connective tissue matrix integrity. These studies highlight the versatile utility of AOD 9604 across both metabolic and orthopedic research vectors.
When designing comparative preclinical protocols, researchers frequently evaluate AOD 9604 alongside related peptides targeting the growth hormone axis or lipid metabolism. The primary direct structural analog is GH Fragment 176-191, which shares the core C-terminal sequence of hGH. However, AOD 9604 incorporates an N-terminal tyrosine modification engineered to enhance stability, bioactivity, and resistance to enzymatic degradation in experimental buffer media.
In contrast to fragment peptides that operate directly on fat tissue pathways without stimulating endogenous growth hormone release, GH secretagogues act higher up the endocrine axis. Compounds such as CJC-1295 bind to growth hormone-releasing hormone (GHRH) receptors on pituitary somatotropes, triggering pulsatile secretion of full-length endogenous hGH. Similarly, Tesamorelin acts as a stabilized GHRH analog targeting pituitary stimulation, producing broad metabolic downstream cascades including elevated circulating IGF-1.
The distinct advantage of AOD 9604 in analytical research is its narrow, targeted mechanism of action. By isolating lipolytic pathways without activating GHRH receptors or raising systemic IGF-1 titers, AOD 9604 allows investigators to study targeted adipose and chondrocyte pathways without the systemic confounding factors introduced by full-spectrum secretagogues.
For research laboratories looking to buy AOD 9604 peptide online, establishing strict supplier qualification criteria is mandatory. Synthetic peptides are susceptible to truncated sequences, incomplete deprotection artifacts, oxidation of sensitive cysteine residues, and aggregated species. Reliable empirical data require high-purity reagents verified by comprehensive batch testing.
At PX1 Research, every production lot of AOD 9604 undergoes mandatory dual-analytical validation at independent, ISO 17025-accredited laboratories. Purity is quantified using Reversed-Phase High-Performance Liquid Chromatography (RP-HPLC) with UV detection at 214 nm, ensuring target purity exceeds 98.0%. Sequence mass identity is confirmed using Electrospray Ionization Mass Spectrometry (ESI-MS), matching the observed molecular weight against the theoretical molecular mass of 1815.1 Da.
Furthermore, our quality verification process includes Chromogenic Limulus Amebocyte Lysate (LAL) testing to ensure bacterial endotoxin levels remain strictly below <0.1 EU/mg. Batch-specific Certificates of Analysis (COAs), complete with raw HPLC chromatograms and mass spectra, are published directly on our portal for transparent verification prior to purchase. Laboratories requiring specialized documentation or bulk reagent volumes can coordinate with our specialized team through our wholesale laboratory account portal.
Proper handling and storage of lyophilized AOD 9604 are vital to maintain peptide stability and prevent degradation of the delicate intramolecular disulfide bond. Upon arrival at the research facility, sealed vials of lyophilized AOD 9604 should be stored in a commercial freezer at -20°C (or -80°C for long-term storage) protected from light and moisture.
Before reconstitution, vials must be allowed to equilibrate to room temperature (18°C–22°C) to prevent condensation from forming inside the container upon unsealing. Reconstitution should be performed inside a certified laminar flow hood using sterile, laboratory-grade solvent. Bacteriostatic Water (0.9% benzyl alcohol) or Sterile Normal Saline (0.9% NaCl) is recommended depending on the intended downstream assay requirements.
Gently direct the solvent along the glass inner wall of the vial rather than shooting it directly onto the lyophilized cake. Gently swirl the vial in a smooth circular motion until the cake dissolves completely into a clear, colorless solution; never vortex or agitate vigorously, as shear forces can induce peptide aggregation. Once reconstituted, stock solutions should be stored at 2°C–8°C for short-term use (up to 30 days) or aliquoted into sterile microcentrifuge tubes and frozen at -20°C to avoid repeated freeze-thaw cycles.
PX1 Research stands as a premier US supplier of analytical-grade research peptides, providing academic institutions, biotechnology companies, and private laboratories with reliable compounds. When buying AOD 9604 online from PX1 Research, institutional buyers receive compounds synthesized in domestic, state-of-the-art facilities compliant with current Good Manufacturing Practices (cGMP).
Our commitment to quality control is reinforced by lot-by-lot verification protocols. Unlike vendors that rely on out-of-date or generalized manufacturer test sheets, PX1 Research tests every single batch independently. We provide complete transparency with accessible RP-HPLC and mass spectrometry data for total assurance of structural purity, correct mass identity, and low endotoxin limits.
With fulfillment facilities strategically located in California and Arizona, PX1 Research provides rapid same-day shipping on all orders placed before 3:00 PM EST, Monday through Friday. Our logistics infrastructure minimizes transit duration, reducing temperature stress on shipped reagents. Secure your laboratory's supply of high-purity research peptides with PX1 Research today.
What is the certified chemical purity of PX1 Research AOD 9604?
PX1 Research guarantees an analytical purity of >98.0% for all AOD 9604 batches, verified via Reversed-Phase HPLC. Every lot is accompanied by an independent ISO 17025 COA confirming purity and mass identity via ESI-MS.
How does AOD 9604 differ structurally from GH Fragment 176-191?
AOD 9604 is an modified derivative of hGH fragment 177-191 that includes an added N-terminal tyrosine residue. This modification enhances structural stability and peptide resistance to enzymatic degradation in experimental buffers.
What solvent is recommended for reconstituting AOD 9604 in laboratory settings?
For standard laboratory assays, AOD 9604 is typically reconstituted using sterile Bacteriostatic Water (0.9% benzyl alcohol) or sterile 0.9% Sodium Chloride injection solution, depending on protocol specifications.
What are the storage temperature requirements for lyophilized AOD 9604?
Lyophilized AOD 9604 should be stored at -20°C for short-to-medium term storage, or -80°C for long-term preservation. Vials should be kept in desiccated conditions protected from light exposure.
Does AOD 9604 stimulate IGF-1 release in preclinical models?
No. Preclinical models indicate that AOD 9604 acts specifically on lipolytic and chondrocyte pathways without binding to the hepatic growth hormone receptor domains responsible for IGF-1 induction.
What are the endotoxin limits for PX1 Research peptide products?
PX1 Research enforces strict endotoxin screening using Chromogenic LAL assays, ensuring bacterial endotoxin levels in our AOD 9604 remain below <0.1 EU/mg.
How fast does PX1 Research ship laboratory orders?
Orders placed Monday through Friday before 3:00 PM EST ship same-day from our dual fulfillment centers in California and Arizona to minimize transit time.
Is AOD 9604 approved for human consumption or therapeutic use?
No. AOD 9604 supplied by PX1 Research is strictly designated for laboratory research, in vitro assays, and preclinical chemical evaluation. It is not for human or veterinary use.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.